Polyrizon Ltd. (PLRZ)
NASDAQ: PLRZ · Real-Time Price · USD
12.98
-0.13 (-0.99%)
At close: Mar 9, 2026, 4:00 PM EDT
13.07
+0.09 (0.69%)
After-hours: Mar 9, 2026, 6:57 PM EDT
Company Description
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel.
The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients.
It also develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza blockers.
Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.
Polyrizon Ltd.
| Country | Israel |
| Founded | 2005 |
| IPO Date | Oct 29, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Tomer Izraeli |
Contact Details
Address: 5 Ha-Tidhar Street Ra'anana, 4366507 Israel | |
| Phone | 972 9 374 0120 |
| Website | polyrizon-biotech.com |
Stock Details
| Ticker Symbol | PLRZ |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.38 |
| CIK Code | 0001893645 |
| CUSIP Number | M79549123 |
| ISIN Number | IL0011814113 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Tomer Izraeli | Founder, Chief Executive Officer and Director |
| Nir Ben Yosef | Chief Financial Officer and Compliance Officer |
| Dr. Tidhar Turgeman | Chief Technology Officer |
| Dr. Eyal S. Ron Ph.D. | Chief Scientific Officer |
| Daphna Avital | Chief People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 9, 2026 | SCHEDULE 13G/A | Filing |
| Feb 26, 2026 | 6-K | Report of foreign issuer |
| Feb 6, 2026 | 6-K | Report of foreign issuer |
| Feb 4, 2026 | 6-K | Report of foreign issuer |
| Jan 22, 2026 | 6-K | Report of foreign issuer |
| Jan 8, 2026 | 6-K | Report of foreign issuer |
| Jan 5, 2026 | 6-K | Report of foreign issuer |
| Dec 29, 2025 | 6-K | Report of foreign issuer |
| Dec 19, 2025 | 6-K | Report of foreign issuer |
| Dec 12, 2025 | SCHEDULE 13G | Filing |